BIO-TECHNE Corp

Nasdaq: TECH·Minneapolis, Minnesota·

Price
$72.79
Base IV
$13.99

Valuation snapshot

Above bull case

At $72.79, the price is above even our bull case of $22.74.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$13.99
19% of the price · range $7.06–$22.74
Price vs base case
420% above
$72.79 against $13.99
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $7.06 to bull $22.74. Values per share.

Price against each value

Bear case
$7.06
Price 930% above
No growth
…
—
Base case
$13.99
Price 420% above
Researched bygpt-6-sol
Valuation Nov 7, 2026 · Price as of Nov 16, 2026How we got here

What does Bio-techne do?

Bio-Techne provides reagents, instruments, and diagnostic assays to help researchers and pharmaceutical companies conduct biological research, develop drugs, and perform clinical diagnostics.

It brought in $1.2B of sales in the 12 months to Sep 2026.

Led by Kim Kelderman, President and Chief Executive Officer since 2024. Bio-Techne Management Team

Lunaphore COMET spatial biology instrumentImage: Lunaphore, a Bio-Techne brand
Industry
Healthcare
Based in
Minneapolis, Minnesota
Trades on
Nasdaq as TECH

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 14¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 38¢ of every dollar.

  • Making what it sells34¢
  • Research and development8¢
  • Sales, marketing and admin38¢
  • Interest and other costs1¢
  • Tax5¢
  • Left as profit14¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Bio-techne, and for what?

Bio-Techne sells scientific materials, instruments and services used in research, drug development and medical testing. It earns revenue when customers buy its products, including proteins, antibodies, testing tools and diagnostic supplies.

Its customers include universities, pharmaceutical and biotechnology companies, clinical laboratories and diagnostic equipment makers.

  • Protein Sciences

    72%

    Proteins, antibodies and other research materials, plus instruments and tests used to study proteins.

  • Diagnostics and Spatial Biology

    28%

    Diagnostic supplies and test kits, plus tools that show where biological signals appear within tissue.

    Lunaphore COMET spatial biology instrumentImage: Lunaphore, a Bio-Techne brand
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • St. Paul GMP facility — Saint Paul, United States. This 61,000-square-foot facility provides large-scale production capacity for GMP-grade proteins and other materials used in cell and gene therapies.
  • ProteinSimple San Jose facility — San Jose, United States. The 98,000-square-foot ProteinSimple manufacturing and warehouse site supports Bio-Techne’s proteomic analytical tools business.
  • Wallingford immunoassay facility — Wallingford, United States. The expanded facility manufactures Simple Plex cartridges for the Ella immunoassay platform and was designed to increase cartridge capacity to 500,000 per year.
  • Bristol GMP small-molecule facility — Bristol, United Kingdom. The operational 10,000-square-foot facility adds GMP-grade small-molecule capacity for customers developing cell therapies.
  • Advanced Cell Diagnostics Newark facility — Newark, United States. The 56,000-square-foot manufacturing site supports Advanced Cell Diagnostics, whose tissue-based in-situ hybridization assays are part of Bio-Techne’s Diagnostics and Spatial Biology segment.
See them on the globe

Bio-Techne fiscal 2026 Form 10-K

How is the business doing?

Sales grew from $931M in 2021 to $1.2B in 2026, about 5% a year.

Running the business leaves about 20¢ of each sales dollar as operating profit, down from 25¢ in 2021.

After paying for its upkeep and new investment, it had $308.2M of cash to spare in the 12 months to Sep 2026.

Sales$1.2B
20172026
Operating margin21%
20172026
Free cash flow$263.2M
20172026
Each bar is one fiscal year (2017–2026), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Bio-Techne says it aims to improve lives by helping science and medicine advance.

“we improve quality of life worldwide by catalyzing advances in science and medicine”

Bio-Techne company website

Who is responsible for the plan?

  • Kim KeldermanPresident and Chief Executive Officer

    He leads Bio-Techne as its president and chief executive officer. Bio-Techne sells life-science reagents, instruments and services for research, diagnostics and bioprocessing.

  • Will GeistPresident, Protein Sciences Segment

    He leads Bio-Techne’s Protein Sciences segment. The segment sells biological reagents and protein-analysis tools used in research, diagnostics and cell and gene therapy.

  • Gary LathamVice President and Chief Technology Officer

    He leads Bio-Techne’s technology function as chief technology officer. Bio-Techne sells products that include genetic and oncology kits for research and clinical applications.

Roles checked November 7, 2026.

What management says it is working on now:

  • Complete the proposed acquisition

    Management is working toward the planned acquisition by Merck KGaA, Darmstadt, Germany. Shareholders have approved it, but remaining regulatory approvals and other closing conditions still apply.

    Bio-Techne shareholder approval announcement
  • Develop new research tools

    Bio-Techne plans to keep investing in research and development to bring out tools that meet changing customer needs.

    Bio-Techne fiscal 2026 Form 10-K
  • Expand into diagnostics and therapies

    Management plans to use its research products and acquired technologies to serve more diagnostic and therapy customers.

    Bio-Techne fiscal 2026 Form 10-K
  • Make buying easier

    The company plans to expand its sales teams and distribution channels worldwide and improve customer service.

    Bio-Techne fiscal 2026 Form 10-K
Revenue growth, Fiscal 2027
At least mid-single-digit growth; management described this as an expectation, not formal guidance
Bio-Techne fiscal 2026 third-quarter earnings call transcript
Cell therapy business growth, Ongoing measure discussed in May 2026
At least 20% growth over a trailing 12-month period
Bio-Techne fiscal 2026 third-quarter earnings call transcript
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is picking up. In Q1 2027 it sold 5% more than a year earlier. The year before, quarters averaged -0%.

Its operating margin is narrower than a year ago: 12¢ per sales dollar, against 17¢.

The share price is about where it was in Oct 2026, near $72.79.

Bull $22.74Base $13.99Bear $7.06Oct 30Nov 16 · $72.79
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Late 2026 or early 2027

    Proposed acquisition closing

    Bio-Techne expects its acquisition by Merck KGaA, Darmstadt, Germany to close after remaining regulatory approvals and other conditions are met. Shareholders approved the agreement in September.

    Bio-Techne shareholder approval announcement
  • By December 31, 2027, or earlier if milestones are met

    Wilson Wolf purchase

    Bio-Techne is required to buy the remaining 80.1% of Wilson Wolf. The purchase could happen sooner if Wilson Wolf meets specified financial milestones.

    Bio-Techne fiscal 2026 Form 10-K

Our own estimate moved too: the base case went from $15.89 to $13.99 a share between our last two valuations. The biggest reason: Capital additions share of sales, fiscal year moved from an unreported prior value to 2.4%, as reported in FY2026 10-K, cash flows and sales.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Research spending may weaken

    Universities, governments and drug developers can reduce or delay research spending. That could mean fewer orders for Bio-Techne's tools and materials.

    From the company's own filingsWould hit how fast sales growBio-Techne fiscal 2026 Form 10-K

  2. Price and product mix pressure

    Fiscal 2026 sales were flat, while pricing pressure and the mix of products sold weighed on profitability. Further pressure could reduce the profit earned on each sale.

    From the company's own filingsWould hit how much of each sale it keepsBio-Techne fiscal 2026 Form 10-K

  3. New products may not gain customers

    The company must keep pace with changing technology and customer needs. Developing a product can be costly, and a finished product may still fail to sell well.

    From the company's own filingsWould hit how fast sales growBio-Techne fiscal 2026 Form 10-K

  4. Diagnostic rules may raise costs

    Some products face extensive medical device rules. Delayed approvals, manufacturing problems or tighter requirements could raise costs or limit sales.

    From the company's own filingsWould hit how much of each sale it keepsBio-Techne fiscal 2026 Form 10-K

  5. Supply interruptions

    Some materials have few qualified suppliers. A shortage or manufacturing disruption could delay deliveries and increase costs.

    From the company's own filingsWould hit how much of each sale it keepsBio-Techne fiscal 2026 Form 10-K

  6. Acquisitions may disappoint

    Acquired businesses and investments may earn less than expected or prove difficult to combine with Bio-Techne. The planned purchase of the rest of Wilson Wolf would also require substantial funding.

    From the company's own filingsWould hit how much it has to reinvestBio-Techne fiscal 2026 Form 10-K

  7. Fiscal 2026 consolidated organic sales were flat, and Diagnostics and Spatial Biology grew only 0.01 organically in the latest quarter.

    From our researchWould hit how fast sales growFY2026 10-K and Q1 FY2027 10-Q

Is it a good business?

From 2017 to 2026 it earned between 4% and 14% on the capital invested in it, a median of 9%. Its cost of capital in the latest valuation is 9.7%; returns were above it in 4 of the 10 years.

From 2017 to 2026 it earned between 4% and 17% on its shareholders' equity, a median of 9%.

Over 10 years its operating margin ranged from 8¢ to 27¢ per sales dollar, a median of 21¢. Gross margin ran from 65¢ to 68¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital10%
20172026

Cost of capital 9.7%

Return on equity9%
20172026
Return on invested capital is operating profit after tax (at the median effective rate, 16%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares grew 6% from 2017 to 2020, so each share owns a smaller slice of the business.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $72.79. Our put its value between $7.06 and $22.74, with $13.99 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $7.06

After nearly flat sales last year, this scenario assumes the recent pickup fades and higher costs keep profits subdued.

Base case, $13.99

After nearly flat sales last year, this scenario assumes the recent pickup continues at a measured pace and profits return to last year's level.

Bull case, $22.74

After nearly flat sales last year, this scenario assumes the recent pickup spreads across the business and stronger sales bring much higher profits.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 420%

For Bio-techne to be worth today's $72.79, sales would need to grow about 51.0% a year. We assume 5.1%. Over the last 5 years, sales grew 4.5% a year.

−20%0%+20%+40%+60%Past 5 yrs 4.5%We assume 5.1%Price needs 51.0%

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 51.0% a year?

Try your own numbers

We're moderately sure of this range: it scores 58 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $13.99 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average5.1%
  • Operating margin21.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$13.99 -80.8%

Build